

Fig.1 Supplementary




Figure S1. Immunophenotype of the HIV-1 specific-CD8⁺ T-cell response after 24h of pembrolizumab administration from week 18 (w18+1). (A) Changes in total CD8⁺ T-cell population (left graph) and, in CD8⁺ T-cell subsets (right graph) after 24h from the administration at week 18. T_N, naïve; T_{CM}, central memory; T_{TM}, transitional memory; T_{EM}, effector memory; T_E, effector; (B) The graphs represent the changes in total CD8⁺ T cells expressing HLA-DR⁺/CD38⁺ (left graph) and, in CD8⁺ T-cell subsets (right graph). T_N, naïve; T_{CM}, central memory; T_{TM}, transitional memory; T_{EM}, effector memory; T_E, effector; (C) Changes of TNF,

IFN γ , CD107a and, IL-2 expression for HIV-1 specific-CD8⁺ T cells in response to HIV-Gag (left graph) and in response to SEB (right graph); **(D)** Frequency of TNF α , IFN γ , CD107a and, IL-2 combinations expressing 1, 2, 3 or 4 cytokines in total HIV-1 specific-CD8⁺ T cells; **(E)** Detailed poly-functional profiles of HIV-1 specific-CD8⁺ T cells. The bars in purple represent the changes on TNF frequency and in pink it is represented the changes of IL-2⁺ and IL-2⁺IFN γ ⁺. **(F)** Total HIV-1 DNA (squares) and cell-associated HIV-1 RNA (circles) in CD4⁺ T cells at week 18+1.